UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: December 2, 2013
(Date of earliest event reported: November 26, 2013)
UNITED HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
814-00717
|
84-1517723
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
c/o Morse & Morse, PLLC
1400 Old Country Road, Suite 302
Westbury, NY 11590
(Address of principal executive offices, zip code)
(516) 487-1452
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
The Board of Directors of the Company has elected Douglas K. Beplate, as Chief Operating Officer of the Company. Mr. Beplate has been working on the development and marketing of the Hemostyp gauze since 2010. Mr. Beplate’s present responsibilities include daily operations and oversight of sales, marketing, product development and intellectual property. From 1996 to 2007, Mr. Beplate was founder and President of Emergency Filtration Products, Inc. (EFP) where his responsibilities included product design, research and development, patent work and production. During his time at EFP, Mr. Beplate was awarded a grant through California State University San Bernardino for development of nanotechnology for the U.S. government and military sector. Prior to his position at EFP he was a consultant to various medical products firms from where he was involved in research and development, and product design.
The Company and Mr. Beplate are negotiating the terms of his employment agreement with the Company. Previously, the Company entered into a Consulting Agreement with Mr. Beplate, the terms of which are described in the Company’s Form 10-Q for the quarter ended September 30, 2013.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
UNITED HEALTH PRODUCTS, INC. | ||
|
|
|
||
|
Dated: December 2, 2013
|
By: |
/s/ Dr. Phillip Forman
|
|
|
|
Dr. Phillip Forman
|
||
|
|
Chief Executive Officer
|
||
3